(Service up to 31 May 2023 服務至 2023年 5月 31日)
Safeguarding public health has long been HKUMed’s core mission, from the 1894 Taipingshan plague to COVID-19. Our health care professionals and scientists have been at the forefront in the battle against COVID-19 since the very beginning of the pandemic. Now, we are supporting the most important phase of pandemic control by operating one of the designated community vaccination centres.
We are responsible for a Community Vaccination Centre where we will administer the COVID-19 mRNA Vaccine: Comirnaty (BNT 162b2) from Fosun Pharma/BioNTech.
At the same time, we are also carrying out lifesaving research into further ensuring the safety and effectiveness of vaccines, to give added protection for those who choose to enrol in our research programmes and more broadly to advance the science of vaccinology against COVID-19. We are recruiting volunteers for vaccination research studies that will produce new knowledge for the next stage of COVID-19 control.
Starting from 11 January 2023, “HKU Community Vaccination Centre at Gleneagles Hospital Hong Kong” provides Fosun/BioNTech Comirnaty vaccination to eligible persons aged 12 or above on Mondays, Wednesdays, Thursday and Fridays. It also provides Fosun/BioNTech Comirnaty bivalent vaccine to eligible recipients aged 12 or above for the third / fourth / fifth dose (or second / third / fourth dose for persons with prior COVID-19 infection). “HKU Children Community Vaccination Centre at Gleneagles Hospital Hong Kong” provides Fosun/BioNTech Comirnaty vaccination to children aged 6 months to 4 on Tuesdays and Sundays, and to children aged 5 to 11 on Saturdays.
Starting from 10 October 2022, the Centre also offers free seasonal influenza vaccination (SIV) to eligible Hong Kong residents aged 50 or above when they are there for COVID-19 vaccination.
For booking vaccination and more details of COVID-19 vaccination programme, please visit the Government’s website: www.covidvaccine.gov.hk.
由1894年太平山鼠疫，到今天新冠肺炎大流行，港大醫學院一直致力守護香港人健康。我們的醫護及研究人員，早於疫情之初，已在抗疫戰前線奮鬥。
現在來到控制疫情的最重要階段，港大醫學院負責營運其中一間社區疫苗接種中心，替廣大市民接種疫苗，提供由復星醫藥與德國藥廠BioNTech共同研發的信使核糖核酸新冠疫苗「復必泰」(BNT 162b2)。
與此同時，我們已展開研究，進一步確保疫苗安全和效用；為參與研究計劃的人士提供額外保障，並推動醫學界發掘和了解新冠肺炎疫苗更多。我們正為疫苗研究招募參加者，為制定下一階段的抗疫措施提供新見解。
由2023年1月11日起，「香港大學駐港怡醫院社區疫苗接種中心」逢星期一、三、四及五會向12歲或以上合資格人士提供復星／BioNTech復必泰疫苗接種服務。此外，中心亦會為12歲或以上合資格人士提供第三／四／五劑（或為2019冠狀病毒病康復者提供第二／三／四劑）復星／BioNTech復必泰二價疫苗。「香港大學駐港怡醫院兒童社區疫苗接種中心」逢星期二及日為6個月至4歲，逢星期六為 5至11歲兒童提供復星／BioNTech復必泰疫苗接種服務。
由2022年10月10日起，中心亦會於星期一及三為年滿五十歲或以上的合資格香港居民在接種新冠疫苗同時，提供免費流感疫苗接種。
如需預約接種及了解更多疫苗計劃的資訊，請瀏覽政府網站 www.covidvaccine.gov.hk。